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Abstract: Ovarian cancer remains a highly lethal disease due to its late clinical presentation and lack of
reliable early biomarkers. Protein-based diagnostic markers have presented limitations in identifying
ovarian cancer. We tested the potential of phospholipids as markers of ovarian cancer by utilizing
inter-related regulation of phospholipids, a unique property that allows the use of ratios between
phospholipid species for quantitation. High-performance liquid chromatography mass spectrometry
was used to measure phospholipid, lysophospholipid, and sphingophospholipid content in plasma
from patients with benign ovarian masses, patients with ovarian cancer, and controls. We applied both
absolute and relative phospholipid ratios for quantitation. Receiver operating characteristic analysis
was performed to test the sensitivity and specificity. We found that utilization of ratios between
phospholipid species greatly outperformed absolute quantitation in the identification of ovarian
cancer. Of the phospholipids analyzed, species in phosphatidylcholine (PC), lysophosphatidylcholine
(LPC), and sphingomyelin (SM) were found to have great biomarker potential. LPC(20:4)/LPC(18:0)
carried the greatest capacity to differentiate cancer from control, SM(d18:1/24:1)/SM(d18:1/22:0) to
differentiate benign from cancer, and PC(18:0/20:4)/PC(18:0/18:1) to differentiate benign from control.
These results demonstrate the potential of plasma phospholipids as a novel marker of ovarian cancer
by utilizing the unique characteristics of phospholipids to further enhance the diagnostic power.
Keywords: lysophospholipids; LC-MS; diagnosis; lipidomics

1. Introduction
Ovarian cancer has the highest mortality among gynecological cancers despite remarkable
advances in the knowledge of molecular biology and treatment [1,2]. These poor outcomes are
attributable to the lack of early presenting symptoms or reliable biomarkers, which limit physicians’
ability to establish an early diagnosis and initiate treatment. Currently, cancer antigen 125 (CA-125)
represents the principle ovarian cancer biomarker; however, while it carries utility in assessing for
cancer resurgence or tracking chemotherapy efficacy, it represents a poor screening tool, detecting
approximately 50% of patients with stage I ovarian cancer. Furthermore, this marker alone is not
recommended to distinguish between benign and malignant adnexal masses [3,4]. As such, pelvic
examination and imaging tests are recommended for initial screening and the initial confirmation of an
adnexal mass; however, these assessments carry similar inability to distinguish benign and malignant
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masses. Currently, the diagnosis of benign or malignant adnexal mass requires histopathologic
examination of a surgically removed tumor [2].
An extensive effort has been made to advance physicians’ armamentarium for ovarian cancer
detection, with the hope that finding a marker with improved sensitivity and specificity will facilitate
earlier detection, treatment, and ultimately improve patient survival. Methods pursued thus far
include proteomics, metabolomics, and lipidomics. However, the vast majority of recent research has
investigated proteomics-based approaches [5]. While CA-125 and other protein-based biomarkers
have demonstrated the most success detecting ovarian cancer thus far, recent studies have found that
implementation of CA-125 in ovarian cancer screening protocols have not made an equivocal impact on
patient survival. As such, no single marker has been implemented successfully to screen asymptomatic
patients or assist in the distinction of benign and malignant ovarian pathology.
Metabolomics and lipidomics promise the potential to assist in ovarian cancer detection. This is
achieved by characterizing the alterations to cellular metabolism associated with cellular transformation
into cancerous processes [6]. Distinct metabolomic profiles have been extensively studied in animal
and human models [7]. However, there has been less success translating these biomarkers towards
consistent and clinically relevant tools. To this end, it is essential to explore the strengths that make
phospholipid biomarkers promising for ovarian cancer surveillance and why recent literature has been
unsuccessful in finding a consistent biomarker.
Phospholipidomics, including the study of lysophospholipids and sphingomyelin, has been
relatively unrecognized as a potential approach towards identifying and characterizing ovarian
pathology. Unlike other plasma lipid metabolites, most phospholipid species are stable with relatively
lower within- and between-individual variations [8]. However, the use of phospholipids for ovarian
cancer so far has not been satisfactory. While studies using global lipidomics approaches have reported
different plasma phospholipids profiles in ovarian cancer patients, these findings were limited by
unsatisfactory sensitivity and/or an absence of benign tumor [9–12]. Furthermore, the sole use of
lysophosphatidic acid (LPA), the most intensively studied phospholipid, also has significant limitations
due to the artificial increase during sample processing, storage, and analysis [13].
Phospholipid species are interrelated [14,15], as such, not only content changes in individual
species but also their relative changes compared to other species are important for characterization of
phospholipids [16,17]. This unique feature of phospholipids allows relative ratios between species
within the same class as a quantitation, which provides a novel approach to identifying phospholipid
biomarkers. The use of a second phospholipid species establishes an endogenous comparator,
theoretically decreasing variability from factors such as sample quantity. Furthermore, more subtle
differences in phospholipid profiles can be amplified by comparing phospholipids, which are elevated
with those that are diminished. Finally, choosing to compare related phospholipid species allows the
ratio to report on the status of a pathophysiologically relevant pathway. This represents an untouched
area of exploration, which may supplement current proteomic and metabolomic biomarkers.
In the present work, we investigate the use of global lipidomics to identify phospholipid
biomarkers with the potential to distinguish control, benign, and cancerous ovarian conditions.
Using an established LC-MS method, we compared phospholipid levels in plasma samples obtained
from patients with ovarian cancer, patients with benign ovarian tumors, and non-cancer controls.
Phospholipids contents were analyzed and compared based on both absolute and relative phospholipid
content. We found significant differences between the phospholipid profile in control, benign, and
cancer groups. These differences were used to develop several phospholipid ratios capable of
distinguishing normal, benign, and cancer groups. In this way, we demonstrate a novel approach
to global lipidomics, validating the use of relative phospholipid content for biomarker analysis.
Furthermore, we identify several promising phospholipid ratios which, with further validation, could
improve ovarian cancer detection and differentiation of benign and cancer.
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2. Results
2.1. LC-MS Analysis of Lysophospholipids
A representative total ion chromatogram and the mass spectra of phospholipids and
lysophospholipids in control samples is shown in Figure S1. Their retention time and MS and MS/MS
data compared to standard phospholipids identified the peaks [18]. The total ion chromatogram shows
major phospholipids present in human plasma, phosphatidylethanolamine (PE), phosphatidylinositol
(PI), phosphatidylcholine (PC), and sphingomyelin (SM). Abundant lysophospholipids, LPC and LPE,
are also visible in the total ion chromatogram. PE contains a significant amount of plasmalogens,
which contain an ether linkage at the sn-1 position (PEP). However, PC plasmalogens (PCP) species
account for only a minor portion of PC.
A previous study showed PEP constituting up to half of the total PE in human plasma [19], which
is consistent with our observations. The MS spectra shows that the PE, PC, and PI species contain
common fatty acids, such as palmitic acid (16:0), stearic acid (18:0), oleic acid (18:1), linoleic acid
(18:2), arachidonic acid (20:4), and docosahexaenoic acid (22:6). LPE and LPC also are constituted with
these major fatty acids. SM contains myristic acid (14:0), arachidic acid (20:0), behenic acid (22:0), and
nervonic acid (24:1). These are fatty acids commonly found in mammalian species, including humans.
We also found unusual SM species such as SM(d18:2/18:0) and SM(d18:2/22:0) with a high abundance.
We provide the MS/MS/MS spectrum of SM(d18:2/18:0) as an example to prove the structure of the
species (Figure S2). The MS/MS/MS spectrum of SM(d18:1/16:0) is also included as a comparison Our
analysis is focused on these major phospholipid species. Our analysis is focused on major phospholipid
species containing these common fatty acids. We have also found less abundant phospholipids such as
phosphatidylglycerol (PG) and phosphatidylserine (PS), but did not include them in this study due
to their insufficient peak intensities, which may be inconsistently detected when interfered by more
abundant ions. We also detected LPA and LPI, which we found to be unstable, resulting in exclusion
from our study [13].
2.2. Phospholipids Content
We first compared the total content of individual classes of phospholipids and lysophospholipids
by normalizing the peak areas to the areas of internal standards. We used PME as an internal standard
for phospholipid species. The ratio can be directly converted to concentration using standard curve as
previously shown [18]. LPE and LPC were normalized using LPE (17:1) and LPC (17:1), respectively.
Figure 1 shows the changes in the normalized total content of each class of phospholipids and
lysophospholipids. The quantitation of PE and PC contains plasmalogens. We found that the total PE
content is ~40% higher in benign and cancer compared to control. SM was higher by ~20% in benign
and cancer. LPE is 30% lower in benign and 15% lower in cancer compared to baseline. LPC is ~20%
lower in benign and cancer than control. Overall, phospholipids contents are generally higher in benign
and cancer than control, whereas lysophospholipids contents are lower in benign and cancer. However,
there is no significant difference in the content of phospholipids or lysophospholipids between benign
and cancer.
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Table 1. The content of phospholipids, lysophospholipids, and sphingomyelin by normalizing the

Tableintensities
1. The content
of phospholipids,
lysophospholipids,
and sphingomyelin by normalizing the
of individual
peak areas to the
areas of internal standards.
intensities of individual peak areas to the areas of internal standards.

Control vs. Benign
Species
Ben/Con
Control vs. Benign
LPE (o-16:0)
0.368
Species
Ben/Con
PE1 (6:0/22:6)
1.832
LPE
0.368
PI(o-16:0)
(18:0/22:6)
1.889
(16:0/22:6)
1.774
PE1PE
(6:0/22:6)
1.832
LPC (18:0)
0.661
PI (18:0/22:6)
1.889
PC (16:0/22:6)
1.779
PE (16:0/22:6)
1.774
LPE (18:1)
0.621
LPC
(18:0)
0.661
PE (o-18:0/22:6)
1.889

p
<0.001
p
<0.001
<0.001
0.001
0.001
<0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.001

Control vs. Cancer
SpeciesControl Can/Con
vs. Cancer
PE (16:0/22:6)
3.155
Species
Can/Con
PE (18:0/22:6)
2.606
PE
(16:0/22:6)
3.155
LPE
(22:6)
1.822

p
<0.001
p
<0.001
<0.001
<0.001

LPC
(22:6)
PE
(18:0/22:6)
PC
(18:0/22:6)
LPE
(22:6)
PC (16:0/22:6)
LPC (22:6)
LPE (18:2)
PC
(18:0/22:6)
LPE
(18:1)

2.276
2.606
1.754
1.822
1.779
2.276
0.648
1.754
0.618

<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.001
<0.001
0.001

Benign vs. Cancer
Species BenignCan/Ben
p
vs. Cancer
PI (18:1/20:4)
0.718
0.014
Species
Can/Ben
p
PE (16:0/18:1)
1.544
0.016
(18:1/20:4)
0.718
0.014
PIPI(18:0/20:4)
0.787
0.040
PI
0.693
0.042
PE(16:0/18:1)
(16:0/18:1)
1.544
0.016
LPC
(22:6)
1.460
0.055
PI (18:0/20:4)
0.787
0.040
SM (d18:1/14:0)
0.724
0.055
PI (16:0/18:1)
0.693
0.042
PI (16:0/20:4)
0.746
0.055
(22:6)
1.460
0.055
SM LPC
(d18:1/23:0)
0.835
0.066

PC (16:0/22:6)

1.779

0.001

PC (16:0/22:6)

1.779

<0.001

SM (d18:1/14:0)

0.724

LPE (18:1)

0.621

0.001

LPE (18:2)

0.648

0.001

PI (16:0/20:4)

0.746

0.055

PE (o-18:0/22:6)

1.889

0.001

LPE (18:1)

0.618

0.001

SM (d18:1/23:0)

0.835

0.066

0.055

Cancers 2020, 12, 72

6 of 14

Table 2. The content of phospholipids, lysophospholipids, and sphingomyelin by normalizing the
intensities of individual peak areas to the total content of phospholipids.
Control vs. Benign

Control vs. Cancer

Benign vs. Cancer

Species

Ben/Con

p

Species

Can/Con

p

Species

Can/Ben

p

LPE (20:4)

1.551

<0.001

LPC (20:4)

2.086

<0.001

SM (d18:1/24:1)

1.196

<0.001

LPE (22:6)

2.134

<0.001

PC (18:0/18:1)

0.771

<0.001

SM (d18:1/22:0)

0.873

0.001

LPE (22:5)

1.659

<0.001

LPE (22:6)

2.168

<0.001

PC (18:0/18:1)

0.888

0.002

PC (18:0/20:4)

1.321

<0.001

LPC (22:6)

2.758

<0.001

SM (d18:1/14:0)

0.790

0.002

LPC (22:6)

1.907

<0.001

LPC (18:0)

0.811

<0.001

LPE (18:2)

0.718

0.002

PE (o-18:0/22:6)

1.327

<0.001

LPC (22:5)

2.330

<0.001

PE (16:0/18:1)

1.434

0.006

LPC (20:4)

1.706

<0.001

SM (d18:1/24:1)

1.261

<0.001

SM (d18:2/22:0)

0.903

0.007

PC (o-18:0/20:4)

1.322

<0.001

SM(d18:1/20:0)

0.819

<0.001

SM(d18:1/23:0)

0.866

0.008

PI (18:0/22:6)

1.566

0.001

PC (16:0/20:4)

1.420

<0.001

PE (o-18:0/18:2)

0.732

0.008

PI (18:0/22:5)

1.382

0.001

PE (16:0/22:6)

2.182

<0.001

SM(d18:1/16:0)

1.050

0.010

PE (o-16:0/22:6)

1.302

0.001

PC (o-18:0/20:4)

1.353

<0.001

PE (o-16:0/18:1)

0.780

0.013

PC (18:0/22:6)

1.382

0.002

SM(d18:1/22:0)

0.840

<0.001

LPC (22:6)

1.446

0.014

LPC (18:0)

0.884

0.002

PE (18:0/22:6)

1.939

<0.001

SM (d18:1/20:0)

0.880

0.016

PE (18:0/18:1)

0.633

0.002

PI (18:0/22:6)

1.684

<0.001

PE (o-16:0/18:2)

0.725

0.020

PC (16:0/20:4)

1.233

0.002

LPE (20:4)

1.370

<0.001

PE (16:0/22:6)

1.467

0.023

PC (18:0/18:1)

0.868

0.002

LPE (22:5)

1.589

<0.001

PC (16:0/16:0)

1.150

0.030

PE (16:0/22:6)

1.487

0.003

SM (d18:1/23:0)

0.853

<0.001

LPC (18:0)

0.917

0.033

PI (18:0/20:4)

1.178

0.003

PC (16:0/22:6)

1.602

<0.001

PC (16:0/20:4)

1.151

0.035

LPC (22:5)

1.823

0.003

SM (d18:1/14:0)

0.764

<0.001

PE (o-16:0/22:6)

0.933

0.035

Between control and cancer, LPE and LPC—including LPEP and LPCP species—show the most
significant differences. PC and SM were also found to be useful to differentiate cancer from control.
In general, species containing long chain fatty acids (14 to 18 carbons) are lower in cancer; unlike species
containing very long change fatty acids (>18 carbons). Between benign and cancer, PE and SM species
show the most difference; PEP are lower in cancer, whereas PE are lower in benign. Our results show
significant differences in the content of metabolites, substantiating the notion that phospholipid species
are interrelated and there is a degree of regulation that exists in the tissues, which gets dysregulated
during tumorigenesis. Although variations were significantly reduced by normalization to the total
content of each class of phospholipids and some species displayed excellent sensitivity and specificity
to distinguish between control and ovarian cancer, none of the species were able to be used to distinctly
distinguish between benign, and benign and cancer.
2.3. Normalization to Other Species Within a Class
We normalized a content of species to another species within the same class. In order to accomplish
this, we chose species whose content was either increased in one group and decreased in another
and determined the ratio between these two species. Using this approach, we identified multiple
combinations that showed excellent separation between the 3 groups. For example, the ratio of SM
(d18:1/24:1) was lower in cancer than in benign, but SM (d18:1/14:0) was higher in cancer. Therefore,
the ratio of SM (d18:1/24:1)/SM (d18:1/22:0) was significantly high in cancer. In this way, we identified
numerous phospholipid pairs, whose ratios are significantly different between the three groups. These
pair markers were further analyzed by receiver operating characteristic (ROC) curve, the top five
markers with best performance are shown in Table 3 and bar graphs and ROC curves of the best
markers are shown in Figure 3 as an example.
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control was 0.87, (b) the AUC of the capacity of the ratios of LPC (20:4)/LPC (18:0) to differentiate
cancer
from
control
was
0.95,
and
(c)(c)
thethe
AUC
of of
thethe
capacity
of of
thethe
ratios
of of
SMSM
(d18:1/24:1)/SM
cancer
from
control
was
0.95,
and
AUC
capacity
ratios
(d18:1/24:1)/SM
(d18:1/22:0)
to
differentiate
benign
from
control
was
0.84.
The
intergroup
difference
was
compared
(d18:1/22:0) to differentiate benign from control was 0.84. The intergroup difference
was
compared
using
the
Mann–Whitney
U
Test.
using the Mann–Whitney U Test.

Figure 3a shows the best area under the curve (AUC) of the ratios of PC(18:0/20:4)/PC(18:0/18:1)
Table 3. The area under curves (AUCs) for phospholipids, lysophospholipids, sphingomyelin, their
with the
capacity to differentiate benign from control at 0.87 (95% CI: 0.77–0.98, p < 0.001) with a cutoff
95% confidence intervals (CI), p values, sensitivities, specificities, and cutoff values for (a) control vs.
value ofbenign,
2.12, a(b)
sensitivity
95%, and
a specificity
73%. Figure 3b shows the best AUC of the ratios
control vs.ofcancer,
and (c)
benign vs. of
cancer.
of LPC (20:4)/LPC (18:0) with the capacity to differentiate cancer from control at 0.95 (95% CI: 0.89–1.00,
(a) Control vs.
PC (18:0/20:4)/PC
(22:6)/LPE
LPC (20:4)/LPC
PC (18:0/22:6)/PC
p < 0.001)
with a cutoff
value of 0.37,LPE
a sensitivity
of LPC
90%,(22:6)/LPC
and a specificity
of 91%. Figure
3c shows
Benign
(18:0/18:1)
(o-16:0)
(18:0)
(18:0)
(18:0/18:1)
the best AUC
of
the
ratios
of
SM
(d18:1/24:1)/SM
(d18:1/22:0)
with
the
capacity
to
differentiate
benign
AUC
0.87
0.86
0.85
0.84
0.83
from control
CI: 0.71–0.96, p <
0.001) with a cutoff
a sensitivity of 90%,
p valueat 0.84 (95%<0.001
<0.001
<0.001value of 1.23,
<0.001
<0.001and a
0.77–0.98
0.74–0.97
0.72–0.97
0.72–0.96
0.71–0.96
95%CI
specificity
of 70%.
Sensitivity (%)
Specificity (%)
Cutoff Value
(b) Control vs.
Cancer
AUC
p value
95%CI
Sensitivity (%)

95
73
2.12
LPC (20:4)/LPC
(18:0)
0.95
<0.001
0.89–1.00
90

100
64
3.9
LPC (22:6)/LPC
(18:0)
0.94
<0.001
0.88–1.00
95

80
86
0.07
LPC (20:4)/LPC
(16:0)
0.94
<0.001
0.87–1.00
80

65
91
0.37
LPC (22:6)/LPC
(o-16:0)
0.92
<0.001
0.84–1.00
95

90
68
0.35
SM (d18:1/24:1)/
SM (d18:1/22:0)
0.92
<0.001
0.83–1.00
100
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Table 3. The area under curves (AUCs) for phospholipids, lysophospholipids, sphingomyelin, their
95% confidence intervals (CI), p values, sensitivities, specificities, and cutoff values for (a) control vs.
benign, (b) control vs. cancer, and (c) benign vs. cancer.
(a) Control vs.
Benign

PC (18:0/20:4)/
PC (18:0/18:1)

LPE (22:6)/
LPE (o-16:0)

LPC (22:6)/
LPC (18:0)

LPC (20:4)/
LPC (18:0)

PC (18:0/22:6)/
PC (18:0/18:1)

AUC
p value
95%CI
Sensitivity (%)
Specificity (%)
Cutoff Value

0.87
<0.001
0.77–0.98
95
73
2.12

0.86
<0.001
0.74–0.97
100
64
3.9

0.85
<0.001
0.72–0.97
80
86
0.07

0.84
<0.001
0.72–0.96
65
91
0.37

0.83
<0.001
0.71–0.96
90
68
0.35

(b) Control vs.
Cancer

LPC (20:4)/
LPC (18:0)

LPC (22:6)/
LPC (18:0)

LPC (20:4)/
LPC (16:0)

LPC (22:6)/
LPC (o-16:0)

SM (d18:1/24:1)/
SM (d18:1/22:0)

AUC
p value
95%CI
Sensitivity (%)
Specificity (%)
Cutoff Value

0.95
<0.001
0.89–1.00
90
91
0.37

0.94
<0.001
0.88–1.00
95
82
0.07

0.94
<0.001
0.87–1.00
80
96
0.14

0.92
<0.001
0.84–1.00
95
82
4

0.92
<0.001
0.83–1.00
100
73
1.13

(c) Benign vs.
Cancer

SM (d18:1/24:1)/
SM (d18:1/22:0)

SM (d18:1/16:0)/
SM (d18:1/22:0)

SM (d18:1/16:0)/
SM (d18:1/14:0)

SM (d18:1/24:1)/
SM (d18:1/14:0)

PE (16:0/18:1)/
PE (o-18:0/18:2)

AUC
p value
95%CI
Sensitivity (%)
Specificity (%)
Cutoff Value

0.84
<0.001
0.71–0.96
90
70
1.23

0.82
<0.001
0.70–0.95
90
65
2.41

0.82
0.001
0.68–0.96
80
80
11.3

0.81
0.001
0.66–0.95
80
85
6.24

0.77
0.003
0.62–0.92
55
100
0.47

2.4. No Changes in the Ratio Occur When the Sample Amount is Altered
To demonstrate the utility of implementing relative phospholipid ratios, we examined the impact
that variation in the quantity of sample collection carries on quantitation using a relative ratio.
We show that when implementing a relative ratio, the species in each class of phospholipids and
lysophospholipids have essentially the same response despite significant sample quantity variations
(25 µL, 50 µL, or 100 µL) (Figure S2). LPC (22:6)/LPE (o-16:0) and SM (d18:1/16:0)/SM (d18:1)/22:0
shows moderate change with the rate of 0.2% /µL and 0.4% /µL, respectively. Even with 10% of pipet
errors, the variation caused by sample amount variation will be less than 3%, which is insignificant.
This establishes an essential component of clinical reliability in the described technique; that species
ratio is unaffected by variance in sample collection.
3. Discussion
Our study provides support for the use of relative phospholipid quantitation in the quantitation of
ovarian cancer biomarkers. Furthermore, we identified multiple phospholipid markers which, in our
patient population, distinguished control vs. benign, control vs. cancer, and benign vs. cancer, with
excellent sensitivity and/or specificity. Among those, LPE (22:6)/LPE (o-16:0) has the best sensitivity in
distinguishing between control and benign, SM (d18:1/24:1)/SM (d18:1/22:0) has the best sensitivity
between control and cancer, and PE (16:0/18:1)/PE (o-18:0/18:2) has the best specificity in distinguishing
between benign and cancer. The existence of multiple markers, which can be quantified through
the same LCMS protocol, facilitates the option to tailor biomarker selection based on the purpose of
diagnosis, e.g., control vs. cancer or benign vs. cancer, without requiring additional testing. Moreover,
multiple markers may provide a unique algorithm to differentiate potential ovarian masses. Future
development of an algorithm that combines these ratios with higher accuracy may improve upon the
predictive power of the previously described phospholipid ratios. Overall, our results demonstrate
that phospholipids have a great potential to serve as novel diagnostic markers for ovarian cancer.
Despite substantial advances in understanding cancer pathology, the survival of ovarian cancer
patients has not been significantly improved in the last 20 years. Time until disease discovery appears
to play an essential role. While early discovery of local ovarian cancer carries a 90% survival, the
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majority of ovarian cancers are diagnosed at a late stage, which carries a 5-year survival less than 30%.
Since the successful screening study shown by Petricoinet et al. [21], a wide variety of protein markers
have been identified [22,23]. However, alongside an inability to demonstrate improved detection
compared to CA-125, proteomics-based biomarkers require significant sample preconditioning to
reduce interference from more abundant proteins [23,24]. In a recent Prospective Phase III trial
utilizing the EPIC cohort, Terry et al. [25], analyzed the diagnostic value of four known or promising
protein biomarkers, CA-125, HE4, CA-72.4, and CA-15.3, in 810 invasive ovarian cancer cases. Their
findings further confirm that CA-125 remains the single best biomarker for early detection of ovarian
cancer, with minimal improvement when combined with other protein biomarkers. These findings
emphasize the need for a variety of ovarian cancer biomarkers, to avoid solely focusing on biomarkers
which rely on CA-125, while also supplementing the diagnostic value of CA-125 in related expressive
ovarian cancers. In this setting, our data clearly show the potential benefit in investigating alternative
biomarkers to supplement CA-125.
Metabolomics provides a rich source of potential supplemental biomarkers. However, this
approach carries two potential weaknesses. Metabolomics and proteomics provide a rich source of
potential supplemental biomarkers, yet each carry inherited weaknesses. Metabolomics and proteomics
are susceptible to variability based on confounding comorbidities and biomarker stability. Factors such
as differences in age, gender, comorbid metabolic diseases, diet, and fasting status can significantly
impact serum levels of metabolites and proteins [26,27]. Furthermore, metabolomics is particularly
susceptible to degradation during sample processing [5]. However, previous research has demonstrated
that phospholipids are less impacted by variability in diet and, with the exception of LPA, are stable
and resistant to degeneration during processing and storage [9].
A unique advantage of phospholipids as a biomarker is the capacity to normalize samples by
total or individual phospholipid content, in addition to using internal standards for quantitation.
Quantitation is a process of sequential normalization of measured peak intensities of metabolites of
interest to the peak intensities of exogenous internal standards, or to a response curve generated using
standard materials and exogenous internal standards [18,28]. This is the commonly used method to
calculate the concentrations of metabolites. The use of an exogenous internal standard through the
calculation of relative ratios significantly reduces variations generated during sample preparation and
analysis. However, sample amount variations and inherent variations due to pipet errors cannot be
corrected by the use of an internal standard, which have a more significant interference than analytical
variations [28]. Variations in sample quantity through provider collection variation and pipet errors can
be corrected by the use of endogenous internal standards, which will also correct analytical variations.
In the current study, we used the ratio of two related phospholipids species, where one species
serves as an endogenous internal standard. This is integral as phospholipids are uniquely regulated in
both dependent and independent pathways. Relative phospholipid quantification allows the absolute
quantity to be normalized against each sample’s contributing phospholipids, decreasing the impact
of sample collection variation on biomarker results. This provides practical utility when analyzing
clinical samples, which can carry significant variation in the amount of sample collected. As such,
quantitation of phospholipid biomarkers in clinical practice should be improved through biomarkers,
which implement a relative ratio.
We found that implementing this ratio significantly reduced the individual species variations
when compared to the concentrations of individual species. Our results emphasize that utilization
of ratios between phospholipid species greatly outperforms quantitation individual species in the
identification of potential ovarian cancer biomarkers, clearly demonstrating the strength of using a
relative ratio over absolute phospholipid content. Furthermore, the use of an endogenous standard via
a phospholipid ratio removes the potential for interprovider variation on sample collection techniques.
This removes a significant clinical variable, which has impacted previous attempts at developing a
phospholipid based ovarian cancer [11]. This analysis represents one of the first investigations to
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identify an ovarian cancer biomarker with the potential to distinguish adnexal mass etiology with
clinically relevant sensitivities and specificity.
In the current study, we limited our analysis to pairing phospholipids sharing the same head
group and similar mass responses. However, molar ratios based on quantitation of individual species
or peak ratios based on completely characterized mass responses will allow for mixed-class analysis,
further improving on the potential power of biomarker selection using this methodology. Regardless
of the application, development of a standard mixture targeting all phospholipid species of interest
will significantly enhance the performance of phospholipids by reducing batch-to-batch and even mass
machine-to-machine variations. The capacity to tailor quantitation methodologies further demonstrates
the unique potential of phospholipids as biomarkers.
A limitation in our study is that further patient demographic information was unable to be
obtained from de-identified sources, as such future work should incorporate potentially confounding
variables such as menstruation status, age variation, iatrogenic estrogen or progesterone use, smoking
status, and past medical conditions such as heart failure. Furthermore, the limited sample number and
selection algorithm increase the risk for overfitting. Future studies are required validating the identified
biomarkers in a separate unique patient population. Future work would also benefit from increased
sample sizes to accommodate for the wide variety in benign and cancerous ovarian conditions. In spite
of these variations, which might have impacted phospholipids profiles in our samples, we clearly
demonstrated that the use of ratios significantly enhanced the diagnostic potential of phospholipids in
detecting ovarian cancer.
4. Materials and Methods
4.1. Materials and Reagents
Reagent-grade chemicals and HPLC-grade solvents were purchased from major commercial suppliers
(Fisher Scientific, Hampton, NH, USA, and Sigma Aldrich, St. Louis, MO, USA). 1,2-Dipalmitoylsn-glycero-3-phospho-N-methylethanolamine (PME) was purchased from Santa Cruz Biotech (Santa
Cruz, CA, USA), and 1-(10Z-heptadecenoyl)-2-hydroxy-sn-glycero-3-phosphocholine (LPC(17:1)),
1-(10Z-heptadecenoyl)-sn-glycero-3-phosphoethanolamine (LPE(17:1)), 1-(10Zheptadecenoyl)-2hydroxy-sn-glycero-3-phospho-(1’-myo-inositol) (LPI(17:1)), and 1-heptadecanoyl-2- hydroxy-snglycero-3-phosphate (LPA(17:0)) were purchased from Avanti Polar Lipids (Alabaster, AL, USA).
Milli-Q water was used throughout.
4.2. Sample Collection and Processing
All plasma samples were collected under protocols approved by the Institutional Review Board at
the Feinstein Institute for Medical Research. Informed consent was obtained from all patients and
controls. (The protocol # is 10-193A). Plasma samples were collected from three groups, patients
with confirmed ovarian cancer (cancer, n = 20, 16 from stage III and IV, and 4 from stage I and
II, 61.7 ± 8.1 years old), benign ovarian tumors (benign, n = 20, 57.8 ± 7.1 years old), and healthy,
non-cancer pathology (control, n = 22, 56.2 ± 5.8 years old) were used. The plasma was separated
from blood specimen collected in EDTA containing tubes using centrifugation and stored at −80 ◦ C
until analyzed.
4.3. Extraction of Phospholipids
Lipids were extracted from the plasma samples following the published method [29]. Briefly,
50 µL of frozen plasma was extracted with 750 µL of methanol with 0.1 nmol of PME, 0.15 nmol
of LPE(17:1), 0.85 nmol of LPC(17:1), 0.45 nmol of LPA(17:0), and 0.1 nmol of LPI(17:1) as internal
standards. The mixture was vortexed for 2 min, incubated for 10 min at 4 ◦ C, and centrifuged for 10 min
at 16,000 g. The supernatant was evaporated to dryness under N2 . The residue was reconstituted in a
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100 µL of solution containing isopropanol (IPA): t-butyl methyl ether (TBME): aqueous ammonium
formate (94 mM) (34:17:5, v:v:v). Finally, 20 µL of the solution was injected into the HPLC-MS.
4.4. HPLC-MS Analysis
The phospholipid mixture was analyzed using normal-phase HPLC-MS [16,30]. Eluent A was
created using IPA: TBME: aqueous ammonium formate (94 mM, pH ~2.5) (34:17:5, v:v:v) with eluent B
containing 100% MeOH. The gradients used for the 35 min chromatogram were as follows: 100% A for
18 min, 100% A to 20% A over 6 min, 20% A for 3 min, 20% A to 100% A over 1 min, and hold 100% A
for 7 min. The flow rate was 0.3 mL/min and the column temperature was 30 ◦ C. MS and MS/MS data
were obtained with an LTQ XL spectrometer (Thermo Scientific, San Jose, CA, USA) operated in the
negative ion mode. The full scan MS data was acquired from 180–2000 m/z. The source parameters
were sheath gas flow (8 U), spray voltage (4 kV), capillary temperature (300 ◦ C), and capillary voltage
(−9 V). MS/MS scan was on the most intense ion in the full-scan spectrum with collision energy of
35 eV. We also performed MS/MS/MS for detailed structural characterization for selected species for
detailed structural analysis.
4.5. Data Analysis
Obtained data was processed using Thermo X-calibur software (version 2.2) [31]. Retention
time and MS and MS/MS data were compared to the control to identify individual species [18].
The concentration of PE and PC includes plasmalogens [30]. PE and PC plasmalogens were denoted
as PEP and PCP, respectively. Species between diacyl PE and PEP were distinguished based on their
molecular weights and fragmentation patterns by MS/MS. The peak areas of individual species were
calculated using M0 and M1 peaks.
4.6. Peak Normalization
We first excluded species whose levels changed during 4 h of incubation at room temperature or
storage in freezer from further analysis. The incubation at room temperature for 4 h is chosen because
clinical samples processed within 4 h of blood drawing are commonly used. After selecting stable and
abundant species, we tried three different approaches for peak normalization. The whole procedure
is summarized in the flow chart (Figure S4). Firstly, we used peak areas normalized to the internal
standards, which calculates concentrations of individual species [18]. For this study, we performed
pseudo-quantitation by normalizing lysophospholipids species to corresponding internal standards,
LPE (17:1), LPC (17:1), or LPI (17:1), and phospholipids species to PME. Secondly, individual species
were normalized to the total content of the class of phospholipids or lysophospholipids. Finally,
individual species were normalized to another species within the same phospholipid class.
4.7. Statistical Analysis
Data were expressed as the mean ± standard deviation (SD) for continuous variables. The ratios of
phospholipids and lysophospholipids were compared using the Mann–Whitney U test for continuous
variables, as appropriate. Receiver operating characteristic (ROC) analysis was performed and the area
under the curve (AUC) was calculated for factors of the ratios of phospholipids and lysophospholipids
in order to assess the accuracy of prediction of ovarian cancer for each factor. To test the stability of
phospholipid and lysophospholipids species, the effect of storage time and incubation time on the
phospholipid levels was examined using regression analysis with linear regression and Spearman’s
correlation coefficients. The p values of less than 0.05 were considered to be statistically significant.
All analyses were performed using the SPSS software package (version 25.0 J SPSS). Heat map
representation of phospholipid profiles in the control, benign, and cancer was generated by Metabo
Analyst software v.4.0 [32].
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5. Conclusions
We showed the potential of plasma phospholipids as a diagnostic marker for ovarian cancer.
By using the relative ratio of phospholipid species, we found multiple biomarkers that have high
sensitivity and specificity for distinguishing between control, benign, and cancerous ovarian masses.
This methodology does not rely on prior protein-based assays but rather uses lipidomics, which is an
efficient and promising approach towards ovarian cancer detection.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/1/72/s1.
Figure S1: The total ion chromatogram and MS spectra of plasma phospholipids, Figure S2: The MS/MS/MS
spectra of SM (d18:1/16:0) and SM (d18:2/18:0), Figure S3: Changes in the ratio of phospholipids depending on
sample amount, Figure S4: Flow chart for study design and biomarker selection procedure.
Author Contributions: T.Y., A.T.L., L.B.B. and J.K. designed the study; T.Y. performed the experiments and
acquired data; T.Y., C.E.K., M.S., R.C.C. and J.K. analyzed the data and wrote the first draft; T.Y., C.E.K., M.S.,
R.C.C, L.B.B., A.T.L. and J.K. contributed to writing or critical revision of the manuscript; J.K. is the guarantor
of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analysis. All authors have read and agreed to the published version of
the manuscript.
Funding: This research was funded by Linda and Dr. Myron Teitelbaum Foundation, Monter Cancer Center at
Northwell Health Cancer Institute, Moms Who Kick, Manhasset Women’s Coalition Against Breast Cancer, Henry
Gabbay, Stand Up 2 Cancer, Partners Council for Women’s Health, and the John L. Lovecchio, MD Gynecologic
Oncology Research Fund.
Conflicts of Interest: The authors declare no conflict of interest.

References
1.

2.

3.
4.
5.
6.

7.
8.

9.

10.

11.

De Angelis, R.; Sant, M.; Coleman, M.P.; Francisci, S.; Baili, P.; Pierannunzio, D.; Trama, A.; Visser, O.;
Brenner, H.; Ardanaz, E.; et al. Cancer survival in europe 1999–2007 by country and age: Results of
eurocare-5-a population-based study. Lancet. Oncol. 2014, 15, 23–34. [CrossRef]
Santaballa, A.; Barretina, P.; Casado, A.; Garcia, Y.; Gonzalez-Martin, A.; Guerra, E.; Lainez, N.; Martinez, J.;
Redondo, A.; Romero, I. Seom clinical guideline in ovarian cancer. Clin. Transl. Oncol. 2016, 18, 1206–1212.
[CrossRef] [PubMed]
Biggs, W.S.; Marks, S.T. Diagnosis and management of adnexal masses. Am. Fam. Phys. 2016, 93, 676–681.
Schwartz, P.E.; Taylor, K.J. Is early detection of ovarian cancer possible? Ann. Med. 1995, 27, 519–528.
[CrossRef]
Montagnana, M.; Benati, M.; Danese, E. Circulating biomarkers in epithelial ovarian cancer diagnosis: From
present to future perspective. Ann. Transl. Med. 2017, 5, 276. [CrossRef]
Turkoglu, O.; Zeb, A.; Graham, S.; Szyperski, T.; Szender, J.B.; Odunsi, K.; Bahado-Singh, R. Metabolomics of
biomarker discovery in ovarian cancer: A systematic review of the current literature. Metabolomics 2016, 12,
60. [CrossRef]
Huang, D.; Gaul, D.A.; Nan, H.; Kim, J.; Fernandez, F.M. Deep metabolomics of a high-grade serous ovarian
cancer triple-knockout mouse model. J. Proteome Res. 2019, 18, 3184–3194. [CrossRef]
Breier, M.; Wahl, S.; Prehn, C.; Fugmann, M.; Ferrari, U.; Weise, M.; Banning, F.; Seissler, J.; Grallert, H.;
Adamski, J.; et al. Targeted metabolomics identifies reliable and stable metabolites in human serum and
plasma samples. PLoS ONE 2014, 9, e89728. [CrossRef]
Zhang, Y.; Liu, Y.; Li, L.; Wei, J.; Xiong, S.; Zhao, Z. High resolution mass spectrometry coupled with
multivariate data analysis revealing plasma lipidomic alteration in ovarian cancer in asian women. Talanta
2016, 150, 88–96. [CrossRef]
Li, J.; Xie, H.; Li, A.; Cheng, J.; Yang, K.; Wang, J.; Wang, W.; Zhang, F.; Li, Z.; Dhillon, H.S.; et al. Distinct
plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry. Oncotarget
2017, 8, 46834–46845. [CrossRef]
Yang, W.; Mu, T.; Jiang, J.; Sun, Q.; Hou, X.; Sun, Y.; Zhong, L.; Wang, C.; Sun, C. Identification of potential
biomarkers and metabolic profiling of serum in ovarian cancer patients using uplc/q-tof ms. Cell. Physiol.
Biochem. 2018, 51, 1134–1148. [CrossRef] [PubMed]

Cancers 2020, 12, 72

12.

13.
14.
15.

16.
17.

18.
19.

20.

21.

22.

23.

24.

25.

26.

27.
28.
29.
30.

13 of 14

Buas, M.F.; Gu, H.; Djukovic, D.; Zhu, J.; Drescher, C.W.; Urban, N.; Raftery, D.; Li, C.I. Identification of novel
candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous
ovarian tumors. Gynecol. Oncol. 2016, 140, 138–144. [CrossRef] [PubMed]
Yagi, T.; Shoaib, M.; Kuschner, C.; Nishikimi, M.; Becker, L.B.; Lee, A.T.; Kim, J. Challenges and inconsistencies
in using lysophosphatidic acid as a biomarker for ovarian cancer. Cancers 2019, 11, 520. [CrossRef] [PubMed]
Vance, J.E. Phosphatidylserine and phosphatidylethanolamine in mammalian cells: Two metabolically
related aminophospholipids. J. Lipid Res. 2008, 49, 1377–1387. [CrossRef] [PubMed]
van der Veen, J.N.; Kennelly, J.P.; Wan, S.; Vance, J.E.; Vance, D.E.; Jacobs, R.L. The critical role of
phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim. Biophys.
Acta Biomembr. 2017, 1859, 1558–1572. [CrossRef] [PubMed]
Kim, J.; Yin, T.; Shinozaki, K.; Lampe, J.W.; Becker, L.B. Potential of lysophosphatidylinositol as a prognostic
indicator of cardiac arrest using a rat model. Biomarkers 2017, 22, 755–763. [CrossRef]
Bascoul-Colombo, C.; Guschina, I.A.; Maskrey, B.H.; Good, M.; O’Donnell, V.B.; Harwood, J.L. Dietary
dha supplementation causes selective changes in phospholipids from different brain regions in both wild
type mice and the tg2576 mouse model of alzheimer’s disease. Biochim. Biophys. Acta 2016, 1861, 524–537.
[CrossRef]
Kim, J.; Hoppel, C.L. Comprehensive approach to the quantitative analysis of mitochondrial phospholipids
by hplc-ms. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2013, 912, 105–114. [CrossRef]
Otoki, Y.; Kato, S.; Kimura, F.; Furukawa, K.; Yamashita, S.; Arai, H.; Miyazawa, T.; Nakagawa, K. Accurate
quantitation of choline and ethanolamine plasmalogen molecular species in human plasma by liquid
chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2017, 134, 77–85. [CrossRef]
Tokuyama, W.; Hashimoto, T.; Li, Y.X.; Okuno, H.; Miyashita, Y. Quantification of neurotrophin-3 mrna in
the rat hippocampal subregions using the rt-pcr-based coamplification method. Brain Res. Brain Res. Protoc.
1999, 4, 407–414. [CrossRef]
Petricoin, E.F.; Ardekani, A.M.; Hitt, B.A.; Levine, P.J.; Fusaro, V.A.; Steinberg, S.M.; Mills, G.B.; Simone, C.;
Fishman, D.A.; Kohn, E.C.; et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002,
359, 572–577. [CrossRef]
Ye, B.; Cramer, D.W.; Skates, S.J.; Gygi, S.P.; Pratomo, V.; Fu, L.; Horick, N.K.; Licklider, L.J.; Schorge, J.O.;
Berkowitz, R.S.; et al. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer:
Identification and characterization using proteomic profiling and mass spectrometry. Clin. Cancer Res. 2003,
9, 2904–2911. [PubMed]
Jackson, D.; Craven, R.A.; Hutson, R.C.; Graze, I.; Lueth, P.; Tonge, R.P.; Hartley, J.L.; Nickson, J.A.;
Rayner, S.J.; Johnston, C.; et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian
cancer. Clin. Cancer Res. 2007, 13, 7370–7379. [CrossRef] [PubMed]
Ye, B.; Skates, S.; Mok, S.C.; Horick, N.K.; Rosenberg, H.F.; Vitonis, A.; Edwards, D.; Sluss, P.; Han, W.K.;
Berkowitz, R.S.; et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived
neurotoxin and cooh-terminal osteopontin fragments for ovarian cancer in urine. Clin. Cancer Res. 2006, 12,
432–441. [CrossRef] [PubMed]
Terry, K.L.; Schock, H.; Fortner, R.T.; Husing, A.; Fichorova, R.N.; Yamamoto, H.S.; Vitonis, A.F.; Johnson, T.;
Overvad, K.; Tjonneland, A.; et al. A prospective evaluation of early detection biomarkers for ovarian cancer
in the european epic cohort. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2016, 22, 4664–4675. [CrossRef]
Sampson, J.N.; Boca, S.M.; Shu, X.O.; Stolzenberg-Solomon, R.Z.; Matthews, C.E.; Hsing, A.W.; Tan, Y.T.;
Ji, B.T.; Chow, W.H.; Cai, Q.; et al. Metabolomics in epidemiology: Sources of variability in metabolite
measurements and implications. Cancer Epidemiol. Biomarker. Prev. 2013, 22, 631–640. [CrossRef]
Nedelkov, D.; Kiernan, U.A.; Niederkofler, E.E.; Tubbs, K.A.; Nelson, R.W. Investigating diversity in human
plasma proteins. Proc. Natl. Acad. Sci. USA 2005, 102, 10852–10857. [CrossRef]
Wu, Y.; Li, L. Sample normalization methods in quantitative metabolomics. J. Chromatogr. A 2016, 1430,
80–95. [CrossRef]
Zhao, Z.; Xu, Y. An extremely simple method for extraction of lysophospholipids and phospholipids from
blood samples. J. Lipid Res. 2010, 51, 652–659. [CrossRef]
Choi, J.; Yin, T.; Shinozaki, K.; Lampe, J.W.; Stevens, J.F.; Becker, L.B.; Kim, J. Comprehensive analysis
of phospholipids in the brain, heart, kidney, and liver: Brain phospholipids are least enriched with
polyunsaturated fatty acids. Mol. Cell. Biochem. 2018, 442, 187–201. [CrossRef]

Cancers 2020, 12, 72

31.

32.

14 of 14

Kim, J.; Lampe, J.W.; Yin, T.; Shinozaki, K.; Becker, L.B. Phospholipid alterations in the brain and heart in a
rat model of asphyxia-induced cardiac arrest and cardiopulmonary bypass resuscitation. Mol. Cell. Biochem.
2015, 408, 273–281. [CrossRef] [PubMed]
Chong, J.; Soufan, O.; Li, C.; Caraus, I.; Li, S.; Bourque, G.; Wishart, D.S.; Xia, J. Metaboanalyst 4.0: Towards
more transparent and integrative metabolomics analysis. Nucleic Acids Res. 2018, 46, W486–W494. [CrossRef]
[PubMed]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

